Skip to main content

ADC Licensing Deal Benchmarks

Median Upfront
$393M
Range: $219M - $612M
Total Deal Value
$2.5B
Range: $1.6B - $3.4B
Royalty Rate
13.4% - 21.9%
Tiered up to 25.9%
Dev Milestones
$526M
Range: $351M - $690M
Model Your Deal

Market Analysis

Antibody-drug conjugates remain one of the hottest modalities in oncology licensing. Phase 2 ADC deals command a median total deal value of $2.5B, with upfront payments ranging from $219M to $612M. The premium reflects strong clinical validation from approved ADCs and a deep pipeline of next-generation linker-payload combinations.

Milestone structures in ADC deals are typically front-loaded toward development milestones ($526M median) because of the technical risk around linker stability, payload potency, and therapeutic index optimization. Regulatory milestones add $841M on average, while commercial milestones can reach $736M.

Royalty rates for ADC licensing transactions typically fall between 13.4% and 21.9% at the base tier, escalating to 17.4%-25.9% on blockbuster sales. The 16% upfront / 84% milestone split is standard for Phase 2 ADC assets with competitive differentiation.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for an ADC licensing deal?
Based on our analysis, Phase 2 ADC licensing deals average $393M in upfront payments, with a range of $219M to $612M depending on target validation, payload novelty, and competitive positioning.
How are ADC deal milestones typically structured?
ADC deals allocate approximately 84% of total deal value to milestones. Development milestones ($526M) make up the largest share, followed by commercial milestones ($736M) and regulatory milestones ($841M).
What royalty rates are standard for ADC out-licensing?
Base royalty rates for ADC transactions range from 13.4% to 21.9%, with tiered escalations reaching 17.4%-25.9% on peak sales exceeding $1 billion. Rates are influenced by target novelty, competitive landscape, and territorial scope.
How do ADC deal terms compare to other modalities?
ADC licensing deals typically command a premium over standard monoclonal antibodies due to the added complexity of linker-payload technology and the demonstrated blockbuster potential of approved ADCs. Total deal values tend to be 20-40% higher than naked antibody deals at equivalent clinical stages.

Related Benchmarks

Bispecific Antibody Deals

View

Breast Cancer Deal Benchmarks

View

Phase 2 Deal Benchmarks

View

Oncology Deal Overview 2026

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating